Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.

Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Iyer S, Shah KJ, Goyal RK.

Exp Clin Cardiol. 2007 Summer;12(2):91-6.

2.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

3.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
4.
5.

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.

Am J Cardiol. 2003 Apr 15;91(8):956-60.

PMID:
12686335
6.
7.

Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

Sharma R, Mahajan M, Singh B, Bal BS, Kant R.

J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498.

PMID:
17388006
8.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
9.

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.

Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):631-5.

PMID:
11214768
10.

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS.

J Cardiovasc Risk. 1999 Apr;6(2):113-6.

PMID:
10353071
11.

Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.

Kardiol Pol. 2004 Jun;60(6):567-77. English, Polish.

PMID:
15334157
12.
13.

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.

Diabetes Care. 2002 Jul;25(7):1198-202.

PMID:
12087019
16.

Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.

Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ.

Am J Cardiol. 2015 Jan 15;115(2):178-82. doi: 10.1016/j.amjcard.2014.10.018. Epub 2014 Oct 31.

PMID:
25432415
17.

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.

Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS.

J Clin Pharmacol. 2003 Aug;43(8):825-30.

PMID:
12953339
18.
19.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
20.

Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.

Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.

Metabolism. 2007 Nov;56(11):1534-41.

PMID:
17950105

Supplemental Content

Support Center